Leaflet ARTESYD 25mg tablets

Product code:
W63073002
Quantity:
112
Indicated for:
chorea in Huntington disease
Route of administration:
oral
Substance:
tetrabenazine (VMAT2 inhibitor)
ATC
N07XX06 — Nervous system | Other nervous system drugs | Other nervous system drugs
Tetrabenazine is a medication used for the treatment of movement disorders associated with Huntington's chorea and other hyperkinetic conditions. It works by reducing dopamine levels in the brain, helping to control involuntary movements.

The medication is taken orally, usually two to three times daily, as directed by a doctor. The dosage is gradually adjusted to minimize the risk of side effects.

Patients should be monitored for potential side effects, such as drowsiness, depression, or extrapyramidal symptoms. It is important for patients to inform their doctor of any unusual symptoms or the use of other medications.

Common side effects include drowsiness, fatigue, depression, and insomnia. In rare cases, severe reactions such as extrapyramidal symptoms or suicidal thoughts may occur. Patients should be informed of these risks before starting treatment.

General data about ARTESYD 25mg

Substance:
tetrabenazine
Date of latest medicines list:
01-03-2022
Product code:
W63073002
Concentration:
25mg
Pharmaceutical form:
tablets
Quantity:
112
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
AOP ORPHAN PHARMACEUTICALS AG - AUSTRIA
Holder:
AOP ORPHAN PHARMACEUTICALS AG - AUSTRIA
Number:
9327/2016/02
Shelf life:
3 years